Evidence map›Paper›PMID 41986500›Full record

Trial reportNature cancer2026

Predictive value of early PSMA upregulation for the response to enzalutamide ±

Louise Emmett, Mina Swiha, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Anthony M Joshua, Andrew Nguyen, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng and 14 more

Abstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Louise EmmettDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia. louise.emmett@svha.org.au.ORCID http://orcid.org/0000-0002-4895-7384
Mina SwihaDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0003-3405-7497
Nathan PapaGarvan Institute of Medical Research, Sydney, New South Wales, Australia.
Shalini SubramaniamNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0003-2138-8633
Megan CrumbakerSt Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Anthony M JoshuaSt Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-5159-4580
Andrew NguyenDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.
Andrew WeickhardtOlivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, Victoria, Australia.
Sze-Ting LeeDepartment of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia.
Siobhan NgDepartment of Oncology, Sir Charles Gairdner Hospital and University of Western Australia, Perth, Western Australia, Australia.
Roslyn J FrancisDepartment of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Jeffrey C GohRoyal Brisbane & Women's Hospital, Herston, Queensland, Australia.
David A PattisonRoyal Brisbane & Women's Hospital, Herston, Queensland, Australia.
Sarennya PathmanandavelDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.
Thomas HopeDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Narjess AyatiDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8482-4119
Michael S HofmanProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Shahneen SandhuSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-8660-4475
Claire NiuNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Andrew J MartinNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Hayley ThomasNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Martin R Stockler *NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0003-3793-8724
Ian D Davis *Monash University Eastern Health Clinical School, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-9066-8244
Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group

Funding

Prostate Cancer Foundation (PCF) Challenge Award 2023
6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) receptor expression alters with androgen blockade in metastatic castrate-resistant prostate cancer (mCRPC). We evaluated the frequency and significance of early PSMA-positron emission tomography (PET) standardized uptake value (SUV) mean change with enzalutamide ±

Indexed as

Antigens, SurfaceDipeptidesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantAgedBenzamidesHumansLutetiumMaleMiddle AgedNitrilesPositron Emission Tomography Computed TomographyProstate-Specific AntigenRadioisotopesAntigens, SurfaceBenzamidesDipeptidesenzalutamideFOLH1 protein, humanGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLutetiumLutetium-177NitrilesPhenylthiohydantoinProstate-Specific AntigenPSMA-617Radioisotopes

Identifiers

PMID41986500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.